Cargando…

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy

Detalles Bibliográficos
Autores principales:	van Boxtel, Wim, van Herpen, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570469/ https://www.ncbi.nlm.nih.gov/pubmed/31231462 http://dx.doi.org/10.18632/oncotarget.27004

Ejemplares similares

Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
por: van Boxtel, Wim, et al.
Publicado: (2019)

Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
por: Boon, Eline, et al.
Publicado: (2017)

Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
por: Kawakita, Daisuke, et al.
Publicado: (2022)

Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report
por: Wasano, Koichiro, et al.
Publicado: (2018)

Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report
por: Rösch, Manuel, et al.
Publicado: (2023)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature
por: You, Yongfei, et al.
Publicado: (2021)

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
por: Lassche, Gerben, et al.
Publicado: (2021)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
por: Krens, Stefanie D., et al.
Publicado: (2021)

Assessing salivary matrix metalloproteinase‐8 in prostate cancer patients undergoing androgen deprivation therapy
por: Memon, Maaz A., et al.
Publicado: (2022)

A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands
por: Boon, Eline, et al.
Publicado: (2018)

Case Report: Two Cases of Salivary Duct Carcinoma in Workers With a History of Chromate Exposure
por: Seçin, Imran, et al.
Publicado: (2021)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
por: Park, Sejun, et al.
Publicado: (2011)

Financial toxicity differences between chemical versus surgical androgen deprivation therapy
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2022)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Sternberg, Cora N
Publicado: (2016)

Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
por: Berendika, Jelena, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
por: Ohashi, Toshio, et al.
Publicado: (2014)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
por: van Oostwaard, Marsha M., et al.
Publicado: (2022)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

(68)Ga–Prostate-Specific Membrane Antigen-11–Avid Cardiac Metastases in a Patient With Adenoid Cystic Carcinoma, A Rare Presentation of a Rare Cancer
por: Uijen, Maike José Maria, et al.
Publicado: (2020)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_07t3e7h4hupaoekkj6f5ahnr3d